Oncolytic Viruses: Monotherapies vs. Combination Therapy

Deep Dive into Combinations with PD-1/PD-L1 Inhibitors and CAR-T Therapies

In recent years, the field of cancer therapeutics has witnessed a growing interest in the study of oncolytic viruses (OVs) as part of combination therapy regimens . Although current approvals for OV treatments are primarily for monotherapy, emerging evidence suggests that they exhibit enhanced efficacy when utilized in conjunction with other therapies. The combination of OVs with other treatments, including PD-1/PD-L1 inhibitors and CAR-T cell therapies , holds great promise in improving cancer treatment outcomes.

Access Beacon’s latest report to explore the rationale behind combining OVs with different treatment modalities, as opposed to using monotherapies, and view the positive results observed in current trials.